Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALKS 7290 as Adjunctive Therapy in Major Depressive Disorder
NCT07901179Phase 2Recruiting
- Sponsor
- Alkermes
- Start
- Oct 2026
- Primary completion
- Jan 2028
- Countries
- 1
01
Overview
A Phase 2 trial of ALKS 7290 in major depressive disorder (MDD), sponsored by Alkermes. Started Oct 2026; status: recruiting.
02
Drugs
ALKS 7290
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT07901179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07901179.